Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ALN-TTRSC (revusiran) for subcutaneous administration
ALN-TTRSC for administration · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-TTRSC (revusiran) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALN-TTRSC (revusiran) for subcutaneous administration | DRUG | - |
Inclusion Criteria: * TTR cardiac amyloidosis; * Women of child-bearing potential (WOCBP) must have a negative pregnancy test, cannot be breast feeding, and must be willing to use 2 highly effective methods of contraception; * Male subjects agree to use appropriate contraception; * Adequate blood c...
ALN-TTRSC is an investigational RNA therapy being developed for TTR-mediated amyloidosis, a rare disease in which transthyretin protein deposits build up in tissues. The Phase 2 study of ALN-TTRSC enrolled patients with transthyretin cardiac amyloidosis, the form affecting the heart. It is not an approved treatment.
ALN-TTRSC is being developed by Alnylam Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker ALNY. The company sponsored the Phase 2 study of the drug in patients with transthyretin cardiac amyloidosis.
ALN-TTRSC is in Phase 2 development. One Phase 2 trial has been completed, and no trials of the drug are currently active. The completed study enrolled 26 patients with transthyretin cardiac amyloidosis and was conducted in the United States and the United Kingdom.
ALN-TTRSC was studied in NCT01981837, a Phase 2 trial titled "Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis." The trial enrolled 26 patients aged 18 years and older, was uncontrolled, and has been completed.
Yes. ALN-TTRSC is also known as revusiran, and the subcutaneous formulation is referred to as ALN-TTRSC (revusiran) for subcutaneous administration. The Phase 2 trial in transthyretin cardiac amyloidosis used the revusiran name in its title.
ALN-TTRSC is not approved. It is an investigational RNA therapy that has completed a single Phase 2 trial in TTR-mediated amyloidosis, specifically transthyretin cardiac amyloidosis, and no trials of the drug are currently active.